News

SIG990 is claimed to have the potential to both reduce erythema and decrease the papules and pustules associated with the disease. The company has already secured approval for

The Docetaxel injection is designed to treat breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer. TPU executive VP and chief operating

The approval is based on data from a pivotal multicenter, randomized, controlled, Phase III trial designed to compare the safety and immunogenicity of Quadracel vaccine with DAPTACEL (DTaP)

Currently, the company is conducting a Phase II trial evaluating the safety and efficacy of ganaxolone as adjunctive therapy for uncontrolled seizures in PCDH19 female pediatric epilepsy, and

In July 2014, the company has secured orphan drug designation from the US Food and Drug Administration (FDA) for RG-012 to treat Alport syndrome. Currently, the company is

Currently, MBX-8025 is being evaluated in high unmet need and orphan diseases. HoFH is characterized by loss-of-function mutations in both alleles of the LDL receptor (LDL-R) gene and

As part of the deal, AstraZeneca will provide funding for a team of investigators at Harvard and will establish an in-house team in Sweden which will work on

AG-348 is a first-in-class, orally available activator of pyruvate kinase-R (PKR) enzymes and the medicine met its primary endpoints in two Phase I healthy volunteer trials including a

NuThrax is a combination of BioThrax (Anthrax Vaccine Adsorbed) and the immunostimulatory oligodeoxynucleotide compound CPG 7909. The contract includes a 30-month base period of performance to develop NuThrax